GENETIC-AF Phase 2B Trial Results Published in the Journal of American College of Cardiology: Heart Failure
01 mai 2019 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 01, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma Announces Steering Committee of Leading International Cardiology and Electrophysiology Experts for PRECISION-AF Phase 3 Clinical Trial
23 avr. 2019 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., April 23, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
HF, TIER, and WP SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers
16 avr. 2019 11h32 HE
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., April 16, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating: HFF, Inc. (NYSE: HF) regarding possible breaches of fiduciary duties and other...
WP, HF, and LABL SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
26 mars 2019 17h24 HE
|
Rigrodsky & Long, P.A.
WILMINGTON, Del., March 26, 2019 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating: Worldpay, Inc. (NYSE: WP) regarding possible violations of law related to...
Dose Response of Beta-Blockers in Adrenergic Receptor Polymorphism Genotypes Paper Published in Circulation: Genomic and Precision Medicine
06 mars 2019 08h00 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., March 06, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma Announces Fiscal Year 2018 Financial Results and Provides Corporate Update
27 févr. 2019 16h15 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., Feb. 27, 2019 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma Updates Special Protocol Assessment Request to FDA for Gencaro Phase 3 Atrial Fibrillation Clinical Trial
20 déc. 2018 16h01 HE
|
ARCA biopharma, Inc.
Phase 3 atrial fibrillation trial planned in population with no effective or FDA approved therapiesPRECISION-AF, planned Phase 3 clinical trial in patients with genotype that responds most favorably...
GENETIC-AF Phase 2B Clinical Trial Results Presented in Late Breaking Presentation at European Society of Cardiology Heart Failure 2018 World Congress
29 mai 2018 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 29, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate Update
08 mai 2018 16h15 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., May 08, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...
ARCA biopharma and Medtronic Extend Gencaro Clinical Trial Collaboration Agreement
23 avr. 2018 08h30 HE
|
ARCA biopharma, Inc.
WESTMINSTER, Colo., April 23, 2018 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted...